http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1114998-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_48de1cfdc993735cdc1c82f96827b33e |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6863 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2000-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_437bec2b498d72b167a1b85d503e2ba2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db83ae9fc3a3c9ab4acc9715a45b6d1b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51c29cdcf728e119a652b07bb48599a3 |
| publicationDate | 2001-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1114998-A2 |
| titleOfInvention | Method for determining the success rate of treatment of multiple sclerosis |
| abstract | The invention relates to a method for following the progres and/or treatment of multiplensclerosis on the basis of at least one biological sample obtained from a person suffering from,nor suspected to suffer from, multiple sclerosis, said method comprising the steps of:n a) providing a biological sample derived from a patient suffering from, or suspected to suffernfrom, multiple sclerosis; b) determining the amount of at least one of the cytokines from the group consisting of IL-18,nIL-12p40, IFN-γ, IL-4, IL-10, TGF-β, IL-12Rβ1, IL-12Rβ2 and/or IL-12p35 of said firstnbiological sample; and optionally c) comparing for one or more of the cytokines determined in step b) the value(s) obtained innstep b) with a reference value. n The invention allows determination of the success rate of treatment of multiple sclerosisnby discriminating between patients with multiple sclerosis. In particular, a distinction can benmade between relapsing remitting multiple sclerosis, secondary progressive multiple sclerosisnand primary progressive multiple sclerosis and healthy controls. More particularly theninvention allows determination of the success rate of treatment of multiple sclerosis withninterferon-beta (IFN-β) species such as IFN-β1b and IFN-β1a. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022240597-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2196545-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2196546-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005087255-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7431920-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005087255-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1988175-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016176789-A1 |
| priorityDate | 1999-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 232.